Cargando…
Prognostic Value of Peroxiredoxin-1 Expression in Patients with Solid Tumors: a Meta-Analysis of Cohort Study
METHODS: We comprehensively searched electronic databases, namely, PubMed, Web of Science, EMBASE, Chinese National Knowledge Infrastructure (CNKI), and WanFang databases up to December 2019. Hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated to evaluate the association between...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952178/ https://www.ncbi.nlm.nih.gov/pubmed/33747258 http://dx.doi.org/10.1155/2021/9508702 |
_version_ | 1783663669670838272 |
---|---|
author | Jiao, Lianghe Wei, Jing Ye, Jun Zhang, Chuanmeng |
author_facet | Jiao, Lianghe Wei, Jing Ye, Jun Zhang, Chuanmeng |
author_sort | Jiao, Lianghe |
collection | PubMed |
description | METHODS: We comprehensively searched electronic databases, namely, PubMed, Web of Science, EMBASE, Chinese National Knowledge Infrastructure (CNKI), and WanFang databases up to December 2019. Hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated to evaluate the association between PRDX1 protein expression and the survival of patients with solid tumors. Odds ratios (ORs) with 95% CIs were pooled to estimate the correlation between PRDX1 protein expression and clinicopathologic characteristics in the patients. RESULTS: Seventeen cohort studies that involved 2,858 patients were included in this meta-analysis. The pooled results indicated that positive PRDX1 expression was related to poor overall survival (HR = 1.68, 95% CI: 1.24-2.27, P = 0.001) and disease-free survival (HR = 1.88, 95% CI: 1.31-2.70, P = 0.001). In addition, high PRDX1 expression was associated with large tumor size (OR = 1.69, 95% CI: 1.07-2.68, P = 0.025), advanced TNM stage (OR = 2.26, 95% CI: 1.24-4.13, P = 0.008), and poor tumor differentiation (OR = 0.59, 95% CI: 0.44-0.81, P = 0.001). CONCLUSIONS: PRDX1 overexpression is associated with poor outcomes of cancers and may serve as a prognostic biomarker for malignant patients. Hence, PRDX1 could be a new target for antitumor therapy. |
format | Online Article Text |
id | pubmed-7952178 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-79521782021-03-19 Prognostic Value of Peroxiredoxin-1 Expression in Patients with Solid Tumors: a Meta-Analysis of Cohort Study Jiao, Lianghe Wei, Jing Ye, Jun Zhang, Chuanmeng Dis Markers Research Article METHODS: We comprehensively searched electronic databases, namely, PubMed, Web of Science, EMBASE, Chinese National Knowledge Infrastructure (CNKI), and WanFang databases up to December 2019. Hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated to evaluate the association between PRDX1 protein expression and the survival of patients with solid tumors. Odds ratios (ORs) with 95% CIs were pooled to estimate the correlation between PRDX1 protein expression and clinicopathologic characteristics in the patients. RESULTS: Seventeen cohort studies that involved 2,858 patients were included in this meta-analysis. The pooled results indicated that positive PRDX1 expression was related to poor overall survival (HR = 1.68, 95% CI: 1.24-2.27, P = 0.001) and disease-free survival (HR = 1.88, 95% CI: 1.31-2.70, P = 0.001). In addition, high PRDX1 expression was associated with large tumor size (OR = 1.69, 95% CI: 1.07-2.68, P = 0.025), advanced TNM stage (OR = 2.26, 95% CI: 1.24-4.13, P = 0.008), and poor tumor differentiation (OR = 0.59, 95% CI: 0.44-0.81, P = 0.001). CONCLUSIONS: PRDX1 overexpression is associated with poor outcomes of cancers and may serve as a prognostic biomarker for malignant patients. Hence, PRDX1 could be a new target for antitumor therapy. Hindawi 2021-03-03 /pmc/articles/PMC7952178/ /pubmed/33747258 http://dx.doi.org/10.1155/2021/9508702 Text en Copyright © 2021 Lianghe Jiao et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Jiao, Lianghe Wei, Jing Ye, Jun Zhang, Chuanmeng Prognostic Value of Peroxiredoxin-1 Expression in Patients with Solid Tumors: a Meta-Analysis of Cohort Study |
title | Prognostic Value of Peroxiredoxin-1 Expression in Patients with Solid Tumors: a Meta-Analysis of Cohort Study |
title_full | Prognostic Value of Peroxiredoxin-1 Expression in Patients with Solid Tumors: a Meta-Analysis of Cohort Study |
title_fullStr | Prognostic Value of Peroxiredoxin-1 Expression in Patients with Solid Tumors: a Meta-Analysis of Cohort Study |
title_full_unstemmed | Prognostic Value of Peroxiredoxin-1 Expression in Patients with Solid Tumors: a Meta-Analysis of Cohort Study |
title_short | Prognostic Value of Peroxiredoxin-1 Expression in Patients with Solid Tumors: a Meta-Analysis of Cohort Study |
title_sort | prognostic value of peroxiredoxin-1 expression in patients with solid tumors: a meta-analysis of cohort study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952178/ https://www.ncbi.nlm.nih.gov/pubmed/33747258 http://dx.doi.org/10.1155/2021/9508702 |
work_keys_str_mv | AT jiaolianghe prognosticvalueofperoxiredoxin1expressioninpatientswithsolidtumorsametaanalysisofcohortstudy AT weijing prognosticvalueofperoxiredoxin1expressioninpatientswithsolidtumorsametaanalysisofcohortstudy AT yejun prognosticvalueofperoxiredoxin1expressioninpatientswithsolidtumorsametaanalysisofcohortstudy AT zhangchuanmeng prognosticvalueofperoxiredoxin1expressioninpatientswithsolidtumorsametaanalysisofcohortstudy |